Deborah Dalsin, ATC | |
366 Richland Ave, Apt 2306, Athens, OH 45701-3211 | |
(612) 590-2500 | |
Not Available |
Full Name | Deborah Dalsin |
---|---|
Gender | Female |
Speciality | Preventive Medicine - Sports Medicine |
Location | 366 Richland Ave, Athens, Ohio |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205851185 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083S0010X | Preventive Medicine - Sports Medicine | (Minnesota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Deborah Dalsin, ATC 366 Richland Ave, Apt 2306, Athens, OH 45701-3211 Ph: () - | Deborah Dalsin, ATC 366 Richland Ave, Apt 2306, Athens, OH 45701-3211 Ph: (612) 590-2500 |
News Archive
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.
In a meeting with the Obama administration Monday, Gov. Jan Brewer proposed some Medicaid changes that she hopes will allow Arizona to drop fewer people than previously proposed from the state's Medicaid rolls. Brewer's office already has received permission to cut coverage for 250,000 members, mostly childless adults, as the state tries to close an ongoing budget shortfall.
While x-ray imaging has been used for medical diagnoses for more than a century, scientists have not been able to precisely describe how light moves within nontransparent scintillators – the key component in large area x-ray detectors.
A team of researchers from the Icahn School of Medicine at Mount Sinai and Keck School of Medicine at the University of Southern California have developed a novel machine-learning framework that distinguishes between low- and high-risk prostate cancer with more precision than ever before.
Nucletron, a global leader in radiation oncology, today announced strong financial results over the first half year of 2009. Despite challenging global economic conditions, Nucletron surpassed projections for the first half year.
› Verified 3 days ago